MC2 Partners with EPI for Commercialization of Wynzora – Practical Dermatology
MC2 Therapeutics has entered a Collaboration Agreement with EPI Health, LLC on the commercialization of Wynzora Cream (calcipotriene and betamethasone
MC2 Therapeutics has entered a Collaboration Agreement with EPI Health, LLC on the commercialization of Wynzora Cream (calcipotriene and betamethasone
New topline results in evaluating the efficacy and safety of upadacitinib for adults and adolescents with moderate-to-severe atopic dermatitis (AD) who had an inadequate response…
New research unveils the hidden impact on mental health that some chronic skin conditions take for pediatric patients. The cross-sectional study, published in JAMA Dermatology,…
Step into the ring for the inaugural KOL KNOCKOUT ™ in Oculoplastics! Experts Gary J. Lelli Jr, MD; Nicholas Robert Mahoney, MD; and Prem S.…
Alopecia areata (AA) is known to impact the health-related quality of life (HRQoL) of affected individuals, yet there is a paucity of research focusing on…
Low-dose oral minoxidil (5 mg once daily) was found to have similar effectiveness to topical minoxidil (5% twice per day) for the treatment of male…
A single session of treatment with a fractional carbon dioxide laser followed by botulinum toxin type A was associated with significant reduction of facial pores…
Treatment of psoriasis, vascular lesions, and hypertrophic disorders were the most common non-cosmetic indications for dermatologic use of excimer, vascular, and ablative lasers, respectively, based…
In this episode of DermWire TV, a new analysis highlights factors affecting long-term antibiotic prescriptions for acne; a company developing plaque psoriasis biologics makes a…
A recent analysis of the phase 1b KEYNOTE-041 trial indicated effectiveness and tolerability of pembrolizumab in Japanese patients with advanced melanoma. Researchers conducted the study…
Deucravacitinib, a TYK-2 inhibitor, was linked with significant improvements in patient-reported outcomes (PROs) in patients with active psoriatic arthritis (PsA), according to results from a…